All News

8 December 2008

BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and CommercializationAntibodies

8 December 2008

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNHAntibodies

8 December 2008

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)Antibodies

8 December 2008

Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 MonthsAntibodies

7 December 2008

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual MeetingAntibodies

6 December 2008

Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma TrialAntibodies

6 December 2008

Seattle Genetics Reports Durable Objective Responses with SGN-35 in LymphomaAntibodies

6 December 2008

Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood CancerAntibodies

5 December 2008

YM Biosciences Provides EU Regulatory UpdateAntibodies

5 December 2008

New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn’s Patients With Fistulizing DiseaseAntibodies

4 December 2008

Symphogen and Meiji Seika Kaisha Ltd. Achieve Milestone in Discovery Collaboration for Recombinant Polyclonal Antibody, Sym006Antibodies

4 December 2008

MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 ReceptorAntibodies

4 December 2008

Roche and FDA Agree on Pathway Towards U.S. Approval of Actemra (tocilizumab)Antibodies

3 December 2008

ProtAb, a Wholly Owned Subsidiary of Hadasit Bio Holdings, Receives U.S. Patent for Proximab for the Treatment of RA and Type-1 DiabetesAntibodies

3 December 2008

Conclusion of a joint research agreement between Chiome and Chugai: Innovation in the research and development of therapeutic antibodies by means of the revolutionary “ADLib(R) System” monoclonal antibody identification technologyAntibodies

2 December 2008

UCB announces start of Phase I study for antibody drug candidate CDP6038Antibodies

2 December 2008

Innate Pharma Announces The Entry Into Pre-clinical Validation of IPH 4201, a New Monoclonal Antibody Targeting Pancreatic CancerAntibodies

2 December 2008

Morphotek(R) Inc. Announces Initiation of Farletuzumab Phase II Study In Platinum-Resistant Ovarian CancerAntibodies

1 December 2008

European Commission Approves Erbitux for First-Line Use in Head and Neck CancerAntibodies

1 December 2008

FDA Accepts Cell Therapeutics’ Zevalin sBLA and Grants Priority ReviewAntibodies

28 November 2008

MedImmune Receives FDA Complete Response Letter on MotavizumabAntibodies

26 November 2008

Amorfix Successfully Completes ALS Drug Discovery ProgramAntibodies

26 November 2008

MorphoSys and Galapagos enter alliance to co-develop novel therapeutic antibodies in bone & joint diseaseAntibodies

26 November 2008

Arana commences ART621 Phase II rheumatoid arthritis trialAntibodies

24 November 2008

Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research ProjectsAntibodies

24 November 2008

Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of CancerAntibodies

23 November 2008

Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast CancerAntibodies

21 November 2008

RoActemra Receives Positive Opinion in Europe for the Treatment of Rheumatoid ArthritisAntibodies

21 November 2008

CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric PatientsAntibodies

20 November 2008

Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh- immunization Prevention ProjectAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Mesothelin-Targeted Immunotherapy Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

TSLP Pipeline Review

CD73 Inhibitor Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Report Package: “Drug the Undruggable” Technologies

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics